The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Linomide     2-hydroxy-N,1-dimethyl-4-oxo- N-phenyl...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Linomide


Psychiatry related information on Linomide


High impact information on Linomide

  • These results suggest that linomide prevents cell death triggered by Fas ligation and can be useful for therapeutic intervention in fulminant hepatitis [4].
  • Surviving mice showed severe depletion of cortical thymocytes, but medullar thymic cells expressing high CD3 and Fas levels also survived the treatment with anti-Fas in the presence of linomide [4].
  • Linomide is a synthetic immunomodulator that enhances natural killer cell activity and significantly activates several lymphocytic cell subpopulations in both experimental animals and humans [2].
  • These results suggest that linomide regulates autoimmunity in the absence of systemic immunosuppression [2].
  • Lymphocytes obtained from linomide-treated mice had a reduced in vitro proliferative response to the myelin basic protein and to the tuberculin purified protein derivative, whereas the mitogenic response to concanavalin A was not affected [2].

Chemical compound and disease context of Linomide


Biological context of Linomide


Anatomical context of Linomide

  • Linomide treatment protected mice from passively induced CR-EAE as well, when given from the day of injection with myelin-basic-protein-specific lymphocytes [2].
  • Linomide-treated animals were also resistant to an induced attack by a booster injection with a murine spinal cord homogenate [2].
  • None of the mice (n = 17) that were treated with linomide from day 7 after disease induction developed any clinical or histopathological signs of CR-EAE, as compared to 19 of 20 untreated controls that were severely paralyzed and had extensive demyelinating lesions in the central nervous system [2].
  • The carboxamide-quinoline LS 2616 is a novel immunomodulator augmenting natural killer (NK) cell activity and T-lymphocyte related effector functions [3].
  • Treatment of rats with linomide decreases significantly (P < 0.05), by more than 50%, the number of tumor associated macrophages within both locally invasive (i.e., from 20-40 to 10 macrophages/high power field) and highly metastatic primary prostatic cancers (i.e., from 60-70 to 15-37 macrophages/high power field) [13].

Associations of Linomide with other chemical compounds


Gene context of Linomide


Analytical, diagnostic and therapeutic context of Linomide


  1. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. Joseph, I.B., Isaacs, J.T. J. Natl. Cancer Inst. (1998) [Pubmed]
  2. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Karussis, D.M., Lehmann, D., Slavin, S., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H., Kalland, T., Abramsky, O. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  3. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Kalland, T. Cancer Res. (1986) [Pubmed]
  4. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. Redondo, C., Flores, I., Gonzalez, A., Nagata, S., Carrera, A.C., Merida, I., Martinez-A, C. J. Clin. Invest. (1996) [Pubmed]
  5. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Vukanovic, J., Isaacs, J.T. Cancer Res. (1995) [Pubmed]
  6. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator. Tarkowski, A., Gunnarsson, K., Nilsson, L.A., Lindholm, L., Stålhandske, T. Arthritis Rheum. (1986) [Pubmed]
  7. Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice. del Real, G., Llorente, M., Boscá, L., Hortelano, S., Serrano, A., Lucas, P., Gómez, L., Torán, J.L., Redondo, C., Martínez, C. AIDS (1998) [Pubmed]
  8. Linomide activates the adrenocortical axis in the rat: inhibition of experimental autoimmune encephalomyelitis by linomide is not related to the increase of corticosterone. Weidenfeld, J., Karussis, D., Abramsky, O., Lehmann, D., Arbell, I., Ovadia, H. J. Neuroimmunol. (1997) [Pubmed]
  9. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Zou, L.P., Abbas, N., Volkmann, I., Nennesmo, I., Levi, M., Wahren, B., Winblad, B., Hedlund, G., Zhu, J. Neuropharmacology (2002) [Pubmed]
  10. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Joseph, I.B., Vukanovic, J., Isaacs, J.T. Cancer Res. (1996) [Pubmed]
  11. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras). Rapoport, M.J., Weiss, L., Mor, A., Bistritzer, T., Ramot, Y., Slavin, S. J. Immunol. (1996) [Pubmed]
  12. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. Kalland, T. J. Immunol. (1990) [Pubmed]
  13. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Vukanovic, J., Isaacs, J.T. Cancer Res. (1995) [Pubmed]
  14. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. Kalland, T., Alm, G., Stålhandshe, T. J. Immunol. (1985) [Pubmed]
  15. Abolition of the effect of cyclosporine on rat cardiac allograft rejection by the new immunomodulator LS-2616 (Linomide). Wanders, A., Larsson, E., Gerdin, B., Tufveson, G. Transplantation (1989) [Pubmed]
  16. Protective effect of Linomide on TNF-alpha-induced hepatic injury. Klintman, D., Hedlund, G., Thorlacius, H. J. Hepatol. (2002) [Pubmed]
  17. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Joseph, I.B., Isaacs, J.T. Cancer Res. (1997) [Pubmed]
  18. Interleukin-10 mediates the protective effect of Linomide by reducing CXC chemokine production in endotoxin-induced liver injury. Li, X., Klintman, D., Sato, T., Hedlund, G., Schramm, R., Jeppsson, B., Thorlacius, H. Br. J. Pharmacol. (2004) [Pubmed]
  19. The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. Condiotti, R., Slavin, S., Barak, V., Nagler, A. Leuk. Res. (1996) [Pubmed]
  20. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Karussis, D.M., Lehmann, D., Slavin, S., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H., Ben-Nun, A., Kalland, T., Abramsky, O. Ann. Neurol. (1993) [Pubmed]
WikiGenes - Universities